Share this article on:
COVID19: Bangladesh's Efforts On The Medicine
Beximco Bangladesh to sell a generic version of Remdesivir. It has become the latest sign of
how the push to ensure widespread access to Covid-19 medicines and vaccines has become an urgent issue in poor countries.
BEXIMCO ranked itself as the world’s first company to produce the antiviral drug Remdesivir. by US-based Gilead Sciences originally developed the generic version of the drug.
Remdisivir has grabbed attention as one of the most promising treatments for COVID-19. Gilead has opened up discussions with potential licensing partners, including leading Indian firms, to rapidly scale up supplies of Remdesivir, the antiviral that has received FDA emergency use authorization to tackle COVID-19.
Bangladesh can produce generic versions of patented drugs under WTO provisions that grant the least developed countries a waiver from seeking licenses. The drug will not be supplied through traditional distribution channels. If some governments need the drug, Beximco will export.
Beximco applied for regulatory approval of “Remdesivir” duly completing all the processes, strictly in compliance with local regulations. Following a thorough evaluation, the (DGDA) granted Emergency Use Authorization to Beximco Pharma’s Remdesivir IV Injection on 21 May 2020.
Mr. Zahid Maleque MP, Minister for Health and Family Welfare, Government of the People’s Republic of Bangladesh, lauded Beximco Pharma for its initiatives during this time of the pandemic. It will sell the drug under the brand name Bemsivir.
It will supply Remdesivir (Bemsivir) to Government designated hospitals for COVID-19 treatment. It will not be available through retail pharmacies, in compliance with the directives from Bangladesh drug regulatory authorities.
According to the Bloomberg report, Beximco will sell Remdesivir for about 6,000 takas ($71) a vial to private clinics though it will give it free to state-run hospitals treating COVID-19 patients.
Globally, Covid-19 has infected 5 million people and claimed nearly328,000 lives, according to the WHO. Considering the situation, Remdesivir has generated worldwide interest.
Article by: Sanjida Jannat